Relay Therapeutics, Inc. (RLAY)

Market Cap	1.16B
Revenue (ttm)	8.36M
Net Income (ttm)	-297.59M
Shares Out	173.32M
EPS (ttm)	-1.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	413,207
Open	6.26
Previous Close	6.29
Day's Range	6.17 - 6.67
52-Week Range	1.78 - 7.64
Beta	1.52
Analysts	Strong Buy
Price Target	16.00 (+138.63%)
Earnings Date	Nov 6, 2025

About RLAY

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Kα, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and αGal chaperone for Fabry diseases. It also develops R...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 16, 2020
• Employees: 261
• Stock Exchange: NASDAQ
• Ticker Symbol: RLAY
• Website: https://www.relaytx.com

Financial Performance

In 2024, Relay Therapeutics's revenue was $10.01 million, a decrease of -60.83% compared to the previous year's $25.55 million. Losses were -$337.71 million, -1.25% less than in 2023.

Analyst Summary

According to 9 analysts, the average rating for RLAY stock is "Strong Buy." The 12-month stock price target is $16.0, which is an increase of 138.63% from the latest price.

Price Target

$16.0

(138.63% upside)

Analyst Consensus: Strong Buy